Posted by Michael Wonder on 31 Jan 2025
Rystiggo (rozanolixizumab) for generalised myasthenia gravis receives EU approval for two new administration methods
31 January 2025 - Rystiggo can now be self-administered, or administered by a caregiver, with an infusion pump or manual push with a syringe, after receiving training from a health care professional.
UCB today announced the CHMP has issued a positive opinion for the self-administration of Rystiggo (rozanolixizumab) via an infusion (syringe pump) or a new manual push syringe method, after training from a healthcare professional.
